目的 探讨胃癌组织中IL-6、肿瘤相关巨噬细胞(TAMs)和新生淋巴管的表达的相关性及其与胃癌患者临床病理因素和预后的关系.方法 回顾性分析2012年9月至2013年9月第三军医大学西南医院收治的40例胃癌患者的临床资料.收集患者手术切除的胃组织标本进行研究.采用免疫组织化学染色检测胃癌组织及癌旁组织中IL-6、TAMs特异性抗原CD68、淋巴管特异性蛋白D2-40的表达.分析IL-6、CD68及D2-40间表达的相关性,及其与胃癌患者临床病理因素及预后的关系.采用电话方式进行随访,随访时间截至2014年7月.符合正态分布的计量资料以(x)±s表示,采用t检验,相关性分析采用线性相关分析.IL-6、CD68及D2-40表达与患者临床病理因素的关系采用t检验或方差分析.采用Kaplan-Meier法绘制生存曲线,生存分析采用Log-rank检验.结果 IL-6、CD68和D2-40的表达均位于胃癌组织及癌旁组织细胞的细胞质.胃癌组织中IL-6、CD68、D2-40阳性表达和IL-6与CD68阳性共表达的细胞数分别为(48.0±10.3)个、(26.0±5.5)个、(7.6±3.8)个、(11.4±2.1)个,癌旁组织中其阳性表达的细胞数分别为(11.1±2.3)个、(5.9±1.6)个、(2.5±1.2)个、(2.1±0.7)个,两者上述指标比较,差异均有统计学意义(t=22.021,22.105,8.103,21.893,P＜0.05).胃癌组织中IL-6阳性表达的细胞数与CD68阳性表达的细胞数、D2-40阳性表达的细胞数及IL-6和CD68阳性共表达的细胞数均呈正相关(r=0.941,0.776,0.781,P＜0.05).CD68阳性表达的细胞数与D2-40阳性表达的细胞数呈正相关(r=0.840,P＜0.05).TNM分期为Ⅰ～Ⅱ期的胃癌患者IL-6、CD68、D2-40阳性表达和IL-6与CD68阳性共表达的细胞数分别为(38.6±5.3)个、(21.0±2.2)个、(4.7±1.6)个、(9.7±1.2)个,TNM分期为Ⅲ～Ⅳ期的胃癌患者分别为(57.3±2.6)个、(31.1±1.9)个、(10.6±2.9)个、(13.1±1.3)个;两者上述指标比较,差异均有统计学意义(t=-14.169,-15.509,-8.149,-8.509,P＜0.05).肿瘤浸润深度为T1～T2期的胃癌患者IL-6、CD68、D2-40阳性表达和IL-6与CD68阳性共表达的细胞数分别为(41.5±12.2)个、(22.2±5.1)个、(5.5±2.6)个、(9.7±1.8)个,肿瘤浸润深度为T3～T4期的胃癌患者分别为(50.1±8.8)个、(27.3±5.1)个、(8.3±3.9)个、(12.0±1.9)个;两者上述指标比较,差异均有统计学意义(t=-2.435,-2.770,-2.212,-3.236,P＜0.05).无淋巴结转移的胃癌患者IL-6、CD68、D2-40阳性表达和IL-6与CD68阳性共表达的细胞数分别为(39.2±6.7)个、(21.3±3.0)个、(5.2±3.3)个、(9.8±1.4)个,有淋巴结转移的胃癌患者分别为(55.2±6.4)个、(29.9±3.8)个、(9.6±2.9)个、(12.7±1.6)个;两者上述指标比较,差异均有统计学意义(t=-7.722,-7.838,-4.581,-5.756,P＜0.05).40例患者均获得术后随访,随访时间为6～22个月,中位随访时间为18个月.20例IL-6高表达胃癌患者和20例IL-6低表达胃癌患者的1年累积生存率分别为70.0％、90.0％,两者生存情况比较,差异有统计学意义(x2=4.410,P＜0.05).20例CD68高表达胃癌患者和20例CD68低表达胃癌患者的1年累积生存率分别为70.0％、90.0％,两者生存情况比较,差异有统计学意义(x2=4.075,P＜0.05).20例D2-40高表达胃癌患者和20例D2-40低表达胃癌患者的1年累积生存率分别为65.0％、95.0％,两者生存情况比较,差异有统计学意义(x2=4.705,P＜0.05).20例IL-6和CD68高共表达胃癌患者和20例IL-6和CD68低共表达胃癌患者的1年累积生存率分别为70.0％、90.0％,两者生存情况比较,差异有统计学意义(x2=4.152,P＜0.05).结论 IL-6、TAMs和新生淋巴管在胃癌组织中高表达,IL-6与TAMs、IL-6与新生淋巴管、TAMs与新生淋巴管表达水平均呈正相关,IL-6、TAMs和新生淋巴管与胃癌进展及患者预后密切相关.
目的 探討胃癌組織中IL-6、腫瘤相關巨噬細胞(TAMs)和新生淋巴管的錶達的相關性及其與胃癌患者臨床病理因素和預後的關繫.方法 迴顧性分析2012年9月至2013年9月第三軍醫大學西南醫院收治的40例胃癌患者的臨床資料.收集患者手術切除的胃組織標本進行研究.採用免疫組織化學染色檢測胃癌組織及癌徬組織中IL-6、TAMs特異性抗原CD68、淋巴管特異性蛋白D2-40的錶達.分析IL-6、CD68及D2-40間錶達的相關性,及其與胃癌患者臨床病理因素及預後的關繫.採用電話方式進行隨訪,隨訪時間截至2014年7月.符閤正態分佈的計量資料以(x)±s錶示,採用t檢驗,相關性分析採用線性相關分析.IL-6、CD68及D2-40錶達與患者臨床病理因素的關繫採用t檢驗或方差分析.採用Kaplan-Meier法繪製生存麯線,生存分析採用Log-rank檢驗.結果 IL-6、CD68和D2-40的錶達均位于胃癌組織及癌徬組織細胞的細胞質.胃癌組織中IL-6、CD68、D2-40暘性錶達和IL-6與CD68暘性共錶達的細胞數分彆為(48.0±10.3)箇、(26.0±5.5)箇、(7.6±3.8)箇、(11.4±2.1)箇,癌徬組織中其暘性錶達的細胞數分彆為(11.1±2.3)箇、(5.9±1.6)箇、(2.5±1.2)箇、(2.1±0.7)箇,兩者上述指標比較,差異均有統計學意義(t=22.021,22.105,8.103,21.893,P＜0.05).胃癌組織中IL-6暘性錶達的細胞數與CD68暘性錶達的細胞數、D2-40暘性錶達的細胞數及IL-6和CD68暘性共錶達的細胞數均呈正相關(r=0.941,0.776,0.781,P＜0.05).CD68暘性錶達的細胞數與D2-40暘性錶達的細胞數呈正相關(r=0.840,P＜0.05).TNM分期為Ⅰ～Ⅱ期的胃癌患者IL-6、CD68、D2-40暘性錶達和IL-6與CD68暘性共錶達的細胞數分彆為(38.6±5.3)箇、(21.0±2.2)箇、(4.7±1.6)箇、(9.7±1.2)箇,TNM分期為Ⅲ～Ⅳ期的胃癌患者分彆為(57.3±2.6)箇、(31.1±1.9)箇、(10.6±2.9)箇、(13.1±1.3)箇;兩者上述指標比較,差異均有統計學意義(t=-14.169,-15.509,-8.149,-8.509,P＜0.05).腫瘤浸潤深度為T1～T2期的胃癌患者IL-6、CD68、D2-40暘性錶達和IL-6與CD68暘性共錶達的細胞數分彆為(41.5±12.2)箇、(22.2±5.1)箇、(5.5±2.6)箇、(9.7±1.8)箇,腫瘤浸潤深度為T3～T4期的胃癌患者分彆為(50.1±8.8)箇、(27.3±5.1)箇、(8.3±3.9)箇、(12.0±1.9)箇;兩者上述指標比較,差異均有統計學意義(t=-2.435,-2.770,-2.212,-3.236,P＜0.05).無淋巴結轉移的胃癌患者IL-6、CD68、D2-40暘性錶達和IL-6與CD68暘性共錶達的細胞數分彆為(39.2±6.7)箇、(21.3±3.0)箇、(5.2±3.3)箇、(9.8±1.4)箇,有淋巴結轉移的胃癌患者分彆為(55.2±6.4)箇、(29.9±3.8)箇、(9.6±2.9)箇、(12.7±1.6)箇;兩者上述指標比較,差異均有統計學意義(t=-7.722,-7.838,-4.581,-5.756,P＜0.05).40例患者均穫得術後隨訪,隨訪時間為6～22箇月,中位隨訪時間為18箇月.20例IL-6高錶達胃癌患者和20例IL-6低錶達胃癌患者的1年纍積生存率分彆為70.0％、90.0％,兩者生存情況比較,差異有統計學意義(x2=4.410,P＜0.05).20例CD68高錶達胃癌患者和20例CD68低錶達胃癌患者的1年纍積生存率分彆為70.0％、90.0％,兩者生存情況比較,差異有統計學意義(x2=4.075,P＜0.05).20例D2-40高錶達胃癌患者和20例D2-40低錶達胃癌患者的1年纍積生存率分彆為65.0％、95.0％,兩者生存情況比較,差異有統計學意義(x2=4.705,P＜0.05).20例IL-6和CD68高共錶達胃癌患者和20例IL-6和CD68低共錶達胃癌患者的1年纍積生存率分彆為70.0％、90.0％,兩者生存情況比較,差異有統計學意義(x2=4.152,P＜0.05).結論 IL-6、TAMs和新生淋巴管在胃癌組織中高錶達,IL-6與TAMs、IL-6與新生淋巴管、TAMs與新生淋巴管錶達水平均呈正相關,IL-6、TAMs和新生淋巴管與胃癌進展及患者預後密切相關.
목적 탐토위암조직중IL-6、종류상관거서세포(TAMs)화신생림파관적표체적상관성급기여위암환자림상병리인소화예후적관계.방법 회고성분석2012년9월지2013년9월제삼군의대학서남의원수치적40례위암환자적림상자료.수집환자수술절제적위조직표본진행연구.채용면역조직화학염색검측위암조직급암방조직중IL-6、TAMs특이성항원CD68、림파관특이성단백D2-40적표체.분석IL-6、CD68급D2-40간표체적상관성,급기여위암환자림상병리인소급예후적관계.채용전화방식진행수방,수방시간절지2014년7월.부합정태분포적계량자료이(x)±s표시,채용t검험,상관성분석채용선성상관분석.IL-6、CD68급D2-40표체여환자림상병리인소적관계채용t검험혹방차분석.채용Kaplan-Meier법회제생존곡선,생존분석채용Log-rank검험.결과 IL-6、CD68화D2-40적표체균위우위암조직급암방조직세포적세포질.위암조직중IL-6、CD68、D2-40양성표체화IL-6여CD68양성공표체적세포수분별위(48.0±10.3)개、(26.0±5.5)개、(7.6±3.8)개、(11.4±2.1)개,암방조직중기양성표체적세포수분별위(11.1±2.3)개、(5.9±1.6)개、(2.5±1.2)개、(2.1±0.7)개,량자상술지표비교,차이균유통계학의의(t=22.021,22.105,8.103,21.893,P＜0.05).위암조직중IL-6양성표체적세포수여CD68양성표체적세포수、D2-40양성표체적세포수급IL-6화CD68양성공표체적세포수균정정상관(r=0.941,0.776,0.781,P＜0.05).CD68양성표체적세포수여D2-40양성표체적세포수정정상관(r=0.840,P＜0.05).TNM분기위Ⅰ～Ⅱ기적위암환자IL-6、CD68、D2-40양성표체화IL-6여CD68양성공표체적세포수분별위(38.6±5.3)개、(21.0±2.2)개、(4.7±1.6)개、(9.7±1.2)개,TNM분기위Ⅲ～Ⅳ기적위암환자분별위(57.3±2.6)개、(31.1±1.9)개、(10.6±2.9)개、(13.1±1.3)개;량자상술지표비교,차이균유통계학의의(t=-14.169,-15.509,-8.149,-8.509,P＜0.05).종류침윤심도위T1～T2기적위암환자IL-6、CD68、D2-40양성표체화IL-6여CD68양성공표체적세포수분별위(41.5±12.2)개、(22.2±5.1)개、(5.5±2.6)개、(9.7±1.8)개,종류침윤심도위T3～T4기적위암환자분별위(50.1±8.8)개、(27.3±5.1)개、(8.3±3.9)개、(12.0±1.9)개;량자상술지표비교,차이균유통계학의의(t=-2.435,-2.770,-2.212,-3.236,P＜0.05).무림파결전이적위암환자IL-6、CD68、D2-40양성표체화IL-6여CD68양성공표체적세포수분별위(39.2±6.7)개、(21.3±3.0)개、(5.2±3.3)개、(9.8±1.4)개,유림파결전이적위암환자분별위(55.2±6.4)개、(29.9±3.8)개、(9.6±2.9)개、(12.7±1.6)개;량자상술지표비교,차이균유통계학의의(t=-7.722,-7.838,-4.581,-5.756,P＜0.05).40례환자균획득술후수방,수방시간위6～22개월,중위수방시간위18개월.20례IL-6고표체위암환자화20례IL-6저표체위암환자적1년루적생존솔분별위70.0％、90.0％,량자생존정황비교,차이유통계학의의(x2=4.410,P＜0.05).20례CD68고표체위암환자화20례CD68저표체위암환자적1년루적생존솔분별위70.0％、90.0％,량자생존정황비교,차이유통계학의의(x2=4.075,P＜0.05).20례D2-40고표체위암환자화20례D2-40저표체위암환자적1년루적생존솔분별위65.0％、95.0％,량자생존정황비교,차이유통계학의의(x2=4.705,P＜0.05).20례IL-6화CD68고공표체위암환자화20례IL-6화CD68저공표체위암환자적1년루적생존솔분별위70.0％、90.0％,량자생존정황비교,차이유통계학의의(x2=4.152,P＜0.05).결론 IL-6、TAMs화신생림파관재위암조직중고표체,IL-6여TAMs、IL-6여신생림파관、TAMs여신생림파관표체수평균정정상관,IL-6、TAMs화신생림파관여위암진전급환자예후밀절상관.
Objective To explore the expressions of interleukin-6 (IL-6),tumor-associated macrophages (TAMs) and lymphangiogenesis in the tissues of gastric cancer,and their correlation with the clinicopathological factors and prognosis of patients.Methods The clinical data of 40 patients with gastric cancer who were admitted to the Southwest Hospital from September 2012 to September 2013 were retrospectively analyzed.The surgical specimens from stomach tissues were collected.The expressions of IL-6,TAMs specific antigen (CD68) and lymphatic vessel specific protein (D2-40) in the tumor tissues and adjacent normal tissues were observed by immunohistochemical double staining technique.The correlations among the expressions of CD68 and D2-40,clinicopathological factors and prognosis of patients.The follow-up was carried out on the patients till July 2014.The measurement data with normal distribution were presented as (x) ± s and analyzed by the t test,and the correlation analysis was conducted.The relationship between the expressions of IL-6,CD68 and D2-40 and the clinicopathological factors was analyzed by the t test and the ANOVA.The survival curve was drawn by the Kaplan-Meier method and the survival analysis was done using the Log-rank test.Results The expressions of IL-6,CD68 and D2-40 were located at the cytoplasm of tumor cells and adjacent normal cells.The number of cells with positive expressions of IL-6,CD68 and D2-40 and positive co-expression of IL-6 and CD68 were 48.0 ± 10.3,26.0 ±5.5,7.6 ±3.8,11.4±2.1 in the tumor tissues and 11.1 ±2.3,5.9 ± 1.6,2.5 ± 1.2,2.1 ±0.7 in the adjacent normal tissues,respectively,showing significant differences (t =22.021,22.105,8.103,21.893,P ＜0.05).There were significant positive correlations among the number of cells with positive expressions of IL-6,CD68 and D2-40 and positive co-expression of IL-6 and CD68 in the tumor tissues (r =0.941,0.776,0.781,P ＜ 0.05).There was a significant positive correlation in the number of cells with positive expression between CD68 and D2-40 (r =0.840,P ＜ 0.05).The number of cells with positive expressions of IL-6,CD68 and D2-40 and positive co-expression of IL-6 and CD68 in the patients with gastric cancer of stage Ⅰ-Ⅱ were 38.6 ±5.3,21.0 ±2.2,4.7 ± 1.6 and 9.7 ± 1.2,respectively,which were significantly different from 57.3 ± 2.6,31.1 ± 1.9,10.6 ± 2.9 and 13.1 ± 1.3 in the patients with gastric cancer of stage Ⅲ-Ⅳ (t =-14.169,-15.509,-8.149,-8.509,P ＜ 0.05).The number of cells with positive expressions of IL-6,CD68 and D2-40 and positive co-expression of IL-6 and CD68 in the patients with infiltrative depth of stage T1-T2 were 41.5 ± 12.2,22.2 ±5.1,5.5 ± 2.6 and 9.7 ± 1.8,respectively,which were significantly different from 50.1 ± 8.8,27.3 ± 5.1,8.3 ± 3.9 and 12.0± 1.9 in the patients with infiltrative depth of stage T3-T4 (t =-2.435,-2.770,-2.212,-3.236,P ＜ 0.05).The number of cells with positive expressions of IL-6,CD68 and D2-40 and positive co-expression of IL-6 and CD68 in the patients without lymph node metastases were 39.2 ±6.7,21.3 ±3.0,5.2 ±3.3 and 9.8 ± 1.4,respectively,which were significantly different from 55.2 ± 6.4,29.9 ± 3.8,9.6 ± 2.9 and 12.7 ± 1.6 in the patients with lymph node metastases (t =-7.722,-7.838,-4.581,-5.756,P ＜ 0.05).All the 40 patients were followed up for 6-22 months with a median time of 18 months.The 1-year cumulative survival rate in the 20 patients with high expression of IL-6 was 70.0％,which was significantly different from 90.0％ in the 20 patients with low expression of IL-6 (x2=4.410,P ＜ 0.05).The 1-year cumulative survival rate in the 20 patients with high expression of CD68 was 70.0％,which was significant different from 90.0％ in the 20 patients with low expression of CD68 (x2 =4.075,P ＜ 0.05).The 1-year cumulative survival rate in the 20 patients with high expression of D2-40 was 65.0％,which was significantly different from 95.0％ in the 20 patients with low expression of D2-40 (x2 =4.705,P ＜ 0.05).The 1-year cumulative survival rate in the 20 patients with high co-expression of IL-6 and CD68 was 70.0％,which was significantly different from 90.0％ in the 20 patients with low co-expression of IL-6 and CD68 (x2=4.152,P ＜ 0.05).Conclusions There are high expressions of IL-6,TAMs and lymphangiogenesis in the tissues of gastric cancer,and positive correlations among expressions of IL-6,TAMs and lymphangiogenesis.The expressions of IL-6,TAMs and lymphangiogenesis in the tissues of gastric cancer are significantly correlated with the progression of gastric cancer and prognosis of paitents.
